Reprogramming and gene therapy

199 Biotechnologies develops epigenetic reprogramming therapies, senolytic polyphenol compounds, and affordable longevity diagnostics.

Altos Labs aims to restore cell health and resilience through cell rejuvenation to reverse disease, injury, and life-related disabilities.

BioViva is developing AAV and CMV gene therapy platforms to lengthen healthy human lifespans and treat cellular aging.

clock.health is building a platform for human rejuvenation by decoding genes that enable cells to reverse aging.

Altos Labs works to restore cell health and resilience through cell rejuvenation to reverse disease, injury, and disability.

General Control engineers epigenetic medicines for the complexity of age-related diseases.

Genflow develops SIRT6-based gene therapies intended to slow aging and extend healthy lifespan in humans and dogs.

Junevity develops siRNA therapeutics to reset dysregulated gene networks and reverse complex age-related diseases.

Life Biosciences is a biotechnology company pioneering cellular rejuvenation using epigenetic restoration to reverse diseases of aging.

Mogrify develops in vivo reprogramming therapies to restore lost cell types and organ function directly in situ.

Rejuvenate Bio develops gene therapy treatments for chronic, age-related diseases in companion animals and humans.

Shift Bioscience develops cellular rejuvenation therapies targeting aging cells, including anti-fibrotic siRNA therapeutics for age-driven diseases.

Telocyte seeks to cure Alzheimer's differently by targeting cell aging and telomerase-related gene expression.

Youthereum Genetics sought to fund epigenetic rejuvenation research using an ICO-based decentralized biotech crowdfunding model.

Armatus Bio is a U.S. late-preclinical biotech developing AAV-delivered engineered microRNA therapies for autosomal dominant neuromuscular diseases, with lead programs in CMT1A and FSHD. The strongest project-specific evidence is still preclinical: a 2026 Molecular Therapy: Nucleic Acids paper on AAV9 RNAi for CMT1A in mice and nonhuman primates, a 2026 assay-development paper for potency testing, company and partner press releases on TVR110 and ARM-201, and a pending 2025 PCT patent co-listed with Nationwide Children’s Hospital. The core bet is plausible but unproven in humans, and the main risks are delivery to the right cells at tolerable doses, over-silencing/off-target effects, AAV toxicology, manufacturing consistency, and crowded RNAi/IP competition in both DUX4 and PMP22.

Exomed appears to be an exosome-centered longevity/regenerative project, but the project identity is unusually muddy: the evidence mixes a broad therapeutic-delivery platform pitch, skin/scalp regeneration marketing, a PRP-to-exosome kit, legacy Australian GI-related patents, and an older Australian company record that was cancelled in 2014. The strongest current project-like claim is that Exomed aims to use exosome-based therapies to deliver regenerative signals or targeted payloads to aging or diseased tissues, including possible neurology applications, but there is no project-specific peer-reviewed efficacy dataset in the evidence, so this remains a plausible thesis with weak validation rather than a demonstrated breakthrough.

ExoNovaX appears to map to Kangstem Biotech, a South Korean regenerative-medicine company developing allogeneic umbilical-cord-blood-derived mesenchymal stem cell products, organoid platforms, and related manufacturing capabilities. The strongest project-specific signal is OSCA / Furestem-OA Kit Inj. for knee osteoarthritis, described by the company as combining allogeneic MSCs with an acellular cartilage matrix; however, most direct evidence here is company-controlled website and PR material, while much of the rest is broader field-context patent literature rather than independent validation.

Goda Lab’s longevity-facing program appears to center on engineered small extracellular vesicles (sEVs) for healthspan restoration, with the strongest project-specific signal coming from XPRIZE Healthspan recognition and a secondary-media description of “SHT-sEV therapy.” The core idea is plausible but still weakly validated in the provided evidence: the lab has strong technical depth in imaging, microfluidics, and cell analysis, yet the actual anti-aging therapeutic claims remain mostly self-described or media-described, with explicit unresolved risks around off-target accumulation, safety, and scalable manufacturing.

Hoskinson Health and Wellness Clinic is a Wyoming multi-specialty clinic that presents itself as a longevity- and regenerative-medicine-enabled care model, combining routine clinical services with in-house aging research, specialty care, and claimed regenerative offerings such as PRP, stem-cell-related work, and hyperbaric treatments. The strongest concrete evidence is that it built a substantial regional care footprint and recruited specialist staff, but the record is dominated by self-description, sponsored content, and founder claims, while independent reporting in January-May 2026 shows layoffs, cost pressure, and an announced closure due to lack of financial sustainability.

Marcus STAMINA Team appears to be a U.S.-based geroscience pilot centered on whether intermittent dasatinib plus quercetin can be feasibly given to older adults with slow gait speed and mild cognitive impairment as a senolytic strategy aimed at mobility and cognition; the strongest direct evidence is a 2023 rationale-and-design paper for a 12-week, single-arm, open-label feasibility study in 12 participants, which supports serious academic sponsorship but not efficacy.

Mito-tags appears to be a Stanford/VA-linked mitochondrial delivery project built around bio-modified mitochondria for targeted administration to cells. The strongest project-specific evidence is a pending 2025 PCT patent application and an XPRIZE Healthspan milestone award signal; both support visibility and translational intent, but neither establishes efficacy, safety, or clinical readiness.

This project proposes a safer alternative to blunt telomerase overexpression in mesenchymal stem cells by engineering endogenous TERT regulation as a graded "dimmer switch," aiming to modestly raise telomerase output while preserving native control, stem-cell identity, and genomic stability. The core evidence is a project plan, not outcome data, so the idea is mechanistically plausible but still unproven and exposed to the usual telomerase risks: oncogenic drift, abnormal clonal expansion, telomere dysregulation, and loss of MSC function.

Prometheus Cell Team is presented in 2025 media and social sources as a Shanghai-based XPRIZE Healthspan semifinalist developing autologous “Prometheus Cells” by epigenetically reprogramming patient skin fibroblasts into stem cell-like regenerative cells intended to modulate immunity and promote tissue repair. The core idea is plausible at the field-context level because epigenetic reprogramming and iPSC technologies are well established as research paradigms, but the project-specific evidence here is weak: no primary paper, no protocol, no independent efficacy dataset, and only early, interview-level claims about small planned human testing and hints of immune/telomere improvements.

Rejuvenate Bio is a San Diego startup developing one-time AAV gene therapies for age-related and chronic disease, with the clearest disclosed programs in canine mitral valve disease, desmoplakin arrhythmogenic cardiomyopathy, and partial epigenetic reprogramming. The upside case is unusually ambitious: use liver-directed or systemic gene delivery to create durable, body-wide effects from secreted factors such as FGF21 or from inducible OSK reprogramming. The evidence is still mostly preclinical, often company-reported, and the strongest claims remain limited by mouse or small pilot dog data rather than human validation.

UT Health San Antonio’s "Rejuvenation Through Low Frequency Ultrasound" project is a US-based translational longevity effort testing whether low-frequency ultrasound can reverse cellular senescence without destroying cells. The strongest direct evidence is a 2025 Aging Cell paper with that core claim in its title and authors tied to UTMB and UT Health San Antonio, plus a 2025 university news report that the team became an XPRIZE Healthspan semifinalist and Milestone 1 awardee. The main caveat is that the public evidence here is still thin on quantitative outcomes, with human efficacy and safety not yet established.

RenewalBio is an Israel-based Weizmann spinout and startup developing "stembroids": human iPSC-derived developmental models intended to generate DNA-matched transplantable cells and tissues, with the clearest near-term stated target being hematopoietic stem cell applications for bone marrow failure and related transplant settings. The central promise is large-scale production of authentic, patient-matched replacement cells using embryo-like self-organization rather than conventional expansion, but the evidence here is mostly company, investor, media, and profile material rather than peer-reviewed efficacy or clinical data, so the project should be treated as ambitious and preclinical rather than validated.

The EBIMA Trial appears to sit in a University of Miami clinical-research setting and, based on the evidence provided around mesenchymal-stem-cell and exosome therapeutics, is best understood as a patient-facing regenerative or immunomodulatory therapy project rather than a basic-science effort. The main constraint is evidentiary: the record here contains broad field-context patents and institutional background, but no direct EBIMA protocol, enrollment data, endpoints, or outcomes, so any strong claim about efficacy, indication, or maturity would be overstated.

Unlimited Bio is a promotional longevity startup centered on experimental combination gene therapies, especially VEGF and follistatin, with additional planned programs around KLOTHO, BDNF, PGC-1alpha, and hTERT. The project’s core promise is rejuvenation-oriented functional improvement across muscle, endurance, hair, cognition, and broader anti-aging claims, but the available evidence is mostly project-owned marketing copy with no dated primary results, no independent validation, and explicit disclaimers that the therapies are experimental, not FDA-approved, and delivered by third parties rather than by Unlimited Bio itself.